Hemolytic anemia in wilson disease: Clinical findings and biochemical mechanisms
- 1 November 1980
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 9 (3) , 269-275
- https://doi.org/10.1002/ajh.2830090305
Abstract
Two patients with Wilson disease who presented with severe hemolytic anemia are described. One was noted to have unusually high serum copper levels (369 μg/100 ml). A review of similar such patients in the literature suggests that, rather than having a low serum copper, patients with hemolysis accompanying Wilson disease have very high serum copper levels. For this reason, in vitro studies of the toxic effects of copper on erythrocytes were undertaken. It was found that, although copper does not have a major direct inhibitory effect on glycolytic enzymes such as hexokinase, the metal does inhibit hexokinase as a consequence of its interaction with oxyhemoglobin. However, such inhibition does not appear to be a major factor in copper‐induced hemolysis. On the other hand, the addition of the lipid antioxidant butylated hydroxyanisole (BHA) suppresses hemolysis in copper‐treated cells. These experiments suggest that the primary toxic effect of copper is mediated through its oxidant actions on membrane phospholipids rather than through its potential inhibitory effects on intracellular enzymes.Keywords
This publication has 14 references indexed in Scilit:
- Acute Intravascular Hemolysis and Acute Liver Failure Associated as a First Manifestation of Wilson's DiseaseAnnals of Internal Medicine, 1977
- WILSONʼS DISEASEMedicine, 1975
- Hemolytic Anemia of Wilson’s DiseaseGastroenterology, 1974
- H molytische An mie bei Morbus Wilson (Hepatolentikul re Degeneration)Klinische Wochenschrift, 1972
- The Effect of Copper on Red Cell Enzyme ActivitiesJournal of Clinical Investigation, 1972
- Hemolytic Anemia in Wilson's DiseaseAnnals of Internal Medicine, 1970
- Hemolytic Anemia in Wilson's DiseaseNew England Journal of Medicine, 1967
- THE INCORPORATION OF COPPER INTO CERULOPLASMIN IN VIVO: STUDIES WITH COPPER64 AND COPPER67*Journal of Clinical Investigation, 1961
- Penicillamine, a new oral therapy for Wilson's diseaseThe American Journal of Medicine, 1956
- Studies on Copper Metabolism. XIII. Hepatolenticular Degeneration1Journal of Clinical Investigation, 1954